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Although selective estrogen receptor modulators (SERMs), such as tamoxifen, or aromatase inhibitors
(AIs), such as anastrozole, are the preferred endocrine treatment approach for most patients with hor-
mone receptor-positive breast cancer, many patients progress despite this therapy or become resistant.
Fulvestrant is a selective estrogen receptor down-regulator (SERD) that has demonstrated activity and
efﬁcacy in patients with hormone receptor-positive breast cancer previously untreated or treated with
hormonal therapy. The efﬁcacy of fulvestrant has been demonstrated in the neoadjuvant and metastatic
settings, either alone or in combination with other therapies such as anastrozole or targeted drugs.
Additionally, 500 mg of fulvestrant have been shown to be more effective than 250 mg, without sig-
niﬁcant differences in the toxicity proﬁle. In this review, the unique mode of action of fulvestrant and the
clinical data for different dosing regimens both alone or in combination with other drugs is critically
assessed.
 2014 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-SA license.Introduction
Hormone receptor-positive breast cancer is the most common
presentation of breast cancer today [1]. Several hormonal thera-
peutic options are currently available to treat postmenopausal
women with this disease. The treatment options most extensively
studied are selective estrogen receptor modulators (SERMs) and
aromatase inhibitors (AIs), which constitute the standard thera-
peutic options for this setting. AIs are the standard of care in the
ﬁrst-line treatment of patients with breast cancer. Nonetheless, the: þ34 91 460 33 10.
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opausal and postmenopausal patients with advanced breast cancer
as ﬁrst-line treatment [2]. Eventually, patients develop tumor
progression or resistance to tamoxifen. These patients are often
treatedwith a second-line hormonal therapy [2]. Unfortunately, the
vast majority of patients diagnosed with advanced breast cancer
eventually progress or relapse during or after treatment with any of
these speciﬁc therapies, and additional hormonal agents are
needed to continue treating these patients at time of progression.
Fulvestrant is a estrogen receptor antagonist indicated for the
treatment of postmenopausal women with estrogen receptor-
positive, locally advanced or metastatic breast cancer for disease
relapse on or after adjuvant antiestrogen therapy, or disease pro-
gression on therapy with antiestrogen [3]. Fulvestrant exerts se-
lective estrogen receptor down-regulation (SERD), antiproliferative
activity and induction of apoptosis. Additionally, it does not show
cross-resistance with tamoxifen, or the estrogen receptoreagonist
activity associated with tamoxifen [4]. Fulvestrant has been shown
to be active in patients with breast cancer previously treated with a
SERM such as tamoxifen, or with a non-steroidal AI such as anas-
trozole [5e7].ense.
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as well as the therapeutic role of fulvestrant in the management of
patients with hormone receptor-positive breast cancer. The efﬁcacy
and safety proﬁles of this drug are discussed using data from the
most recent clinical trials of fulvestrant, alone or in combination,
and at doses of 250 and 500 mg.
Mechanism of action and resistance of SERDs
SERDs are antiestrogens that have the main characteristic of
being pure receptor antagonists. Fulvestrant is a SERD that
competitively binds to estrogen receptors, with a binding afﬁnity
approximately 100 times greater than that of tamoxifen [4]. In
animal models, this binding markedly attenuates the ability of the
estrogen receptor to activate or inhibit gene transcription [8]. The
mechanisms that underlie this binding include impaired dimer-
ization, increased estrogen receptor turnover, and disrupted nu-
clear localization [9e11]. However, in contrast to tamoxifen,
binding of fulvestrant to the estrogen receptor induces a rapid
degradation and loss of the estrogen receptor protein in breast
carcinoma cells, making the receptor unavailable or unresponsive
to estrogen or estrogen agonists [12]. Fulvestrant works in a dose-
dependent manner as indicated by the dose-related reduction of
the estrogen receptor index [13]. Another characteristic that dis-
tinguishes the mode of action of fulvestrant from other antiestro-
gens currently in clinical use is that fulvestrant consistently reduces
progesterone receptor levels in the tumor, also in a dose-dependent
manner. Such a feature makes fulvestrant the ﬁrst in a new class of
antiestrogens and SERDs, without any agonist activity [4,14].
After prolonged therapy with fulvestrant, resistance is eventu-
ally acquired in the majority of patients with advanced breast
cancer due to mechanisms that are poorly understood. One of the
most discussed possibilities is the over-expression of the micro-
RNAs miR-221/222. This over-expression in estrogen receptor-
positive cell lines was shown to counteract the effect of estradiol
depletion or of fulvestrant-induced cell death, conferring hormone-
independent growth and fulvestrant resistance [15]. Fig. 1 shows
the mode of action of estradiol and fulvestrant.
Efﬁcacy of fulvestrant in patients with breast cancer
Several preclinical studies have demonstrated that fulvestrant
was markedly more effective than tamoxifen in inhibiting the
in vitro growth of human breast carcinoma cells and was also
effective in tamoxifen-resistant breast carcinoma xenographs inFig. 1. Mode of action of estradiol and fulvestrant. AF1: activation function 1; AF2: activati
fulvestrant; RNA Pol II: ribonucleic acid polymerase II.in vivomouse models [16,17]. Later on, a phase I trial demonstrated
that a short-acting daily formulation of fulvestrant before primary
breast surgery was well tolerated and had antiproliferative and
antiestrogenic effects [18]. Subsequently, several phase II trials
showed the activity of fulvestrant in breast cancer patients previ-
ously treated with tamoxifen and AIs [5,6,19,20]. While clinical
studies have demonstrated a doseeresponse effect in the dose
range of 50e250 mg of fulvestrant for intramuscular use [13], other
trials testing the clinical activity of fulvestrant 125 mg did not show
any objective tumor response after 3 months of treatment [21,22].
Therefore, subsequent clinical development of fulvestrant in
advanced breast cancer was carried out with monthly dosages of
250 mg, although 500 mg have been later tested and compared
with 250 mg.Efﬁcacy of fulvestrant 250 mg
Fulvestrant in comparison with anastrozole
Anastrozole is a highly selective third-generation AI that has
been shown to be modestly superior to tamoxifen in the ﬁrst-line
treatment of advanced breast cancer [23], and to have a statisti-
cally signiﬁcant survival advantage compared with megestrol ace-
tate as a second-line treatment [24]. Also, the use of anastrozole in
the adjuvant setting is now increasing after the results of the Ari-
midex, Tamoxifen, Alone or in Combination (ATAC) trial [25]. The
clinical trial program of fulvestrant at 250 mg incorporated two
multicenter, randomized phase III trials comparing fulvestrant with
anastrozole. One of the trials, Trial 0020, was conducted in Europe,
Australia and South Africa, while the other, Trial 0021, was con-
ducted in North America [21,22]. Each trial compared a once-
monthly intramuscular injection of fulvestrant (250 mg) with a
once-daily oral dose of anastrozole (1 mg) in 851 postmenopausal
women with advanced breast carcinoma who previously had dis-
ease progression after receiving endocrine treatment. The majority
of patients included had received, and progressed on, tamoxifen.
Trials were prospectively designed to allow analysis of com-
bined data [26]. The median TTP was 5.5 months in the fulvestrant
arm and 4.1months in the anastrozole arm (hazard ratio [HR]: 0.95;
95% CI: 0.82e1.10; p ¼ 0.48), and the overall response rate (ORR)
were 19.2% and 16.5% for fulvestrant and anastrozole, respectively
(95% CI: 2.27e9.05; p ¼ 0.31). Although the difference between
treatments was not statistically signiﬁcant, the results satisﬁed the
criteria for demonstrating non-inferiority of fulvestrant compared
with anastrozole. CBR were 43.5% and 40.9% in fulvestrant and
anastrozole arms, respectively (95% CI: 4.42e9.36; p ¼ 0.51). Theon function 2; E: estradiol; ER: estrogen receptor; ERE: estrogen response element; F:
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gression in responding patients was 16.7 months in the fulvestrant
group and 13.7 months in the anastrozole group. In the ITT popu-
lation, fulvestrant achieved a signiﬁcantly longer median duration
of response than anastrozole (HR: 1.30; 95% CI: 1.13e1.50; p< 0.01).
At an extended median follow-up of 27 months, the median overall
survival (OS) was similar between both treatment arms, being 27.4
months compared with 27.7 months in the fulvestrant- and the
anastrozole-treated patients, respectively (HR: 0.98; 95% CI: 0.84e
1.15; p¼ 0.809) [27]. Based on these results, fulvestrant 250mgwas
registered as an additional option for postmenopausal patients
with hormone-sensitive advanced breast cancer that have pro-
gressed on prior endocrine therapy.Fulvestrant in comparison with tamoxifen
Howell et al. reported the ﬁrst randomized trial comparing the
efﬁcacy and tolerability of fulvestrant with tamoxifen as the initial
hormonal treatment of advanced breast cancer in postmenopausal
women [28]. In this multicenter, double-blind, randomized trial,
587 patients with metastatic or locally advanced breast cancer
previously untreated for advanced disease were randomly assigned
to receive either fulvestrant (250 mg) by a monthly intramuscular
injection or tamoxifen (20 mg) orally, once daily. At a median
follow-up of 14.5 months, there was no signiﬁcant difference be-
tween fulvestrant and tamoxifen in terms of median TTP (6.8
months and 8.3 months, respectively; HR: 1.18; 95% CI: 0.98e1.44;
p¼ 0.088). In the subset of patients with estrogen receptor-positive
and/or progesterone receptor-positive tumors (about 78% of pa-
tients), median TTP was 8.2 months for fulvestrant and 8.3 months
for tamoxifen (HR: 1.10; 95% CI: 0.89e1.36; p ¼ 0.39). The ORR for
the overall population was 31.6% for fulvestrant and 33.9% for
tamoxifen (odds ratio [OR]: 0.87; 95% CI: 0.61e1.24; p ¼ 0.45), and
33.2% and 31.1% (OR: 1.10; 95% CI: 0.74e1.63; p¼ 0.64), respectively,
in the hormone receptor-positive subgroup.
The CBR was 54.3% for fulvestrant and 62.0% for tamoxifen for
the overall population (p¼ 0.026), with no signiﬁcant differences in
the subgroup of hormone receptor-positive patients (OR: 0.79; 95%
CI: 15.01e3.19; p ¼ 0.22). Estimated median OS was 36.9 months in
the fulvestrant group and 38.7 months in the tamoxifen group (HR:
1.29; 95% CI: 1.01e1.64; p ¼ 0.04) for the overall population, and
39.3 months compared with 40.7 months (HR: 1.16; 95% CI: 0.88e
1.54; p ¼ 0.30) in the hormone receptor-positive subset of patients,
respectively. It was unexpected that fulvestrant showed neither
superiority nor inferiority to tamoxifen in terms of TTP, but also that
CBR and OS were signiﬁcantly in favor of tamoxifen. In spite of this,
it is important to point out that results were similar in both groups
in the subset of patients with hormone receptor-positive disease.Fulvestrant in comparison with exemestane
The third-generation non-steroidal AIs are increasingly used as
adjuvant and ﬁrst-line advanced therapy for postmenopausal pa-
tients with hormone receptor-positive breast cancer. Due to the fact
that many patients subsequently develop disease progression or
relapse, the identiﬁcation of agents with efﬁcacy after AI failure is a
key aspect in this setting. Taking into account the prevalence of
patients exposed to non-steroidal AI, the Evaluation of Faslodex
versus Exemestane Clinical Trial (EFECT) was undertaken to
determine the optimal hormonal agent to be administered after
progression on non-steroidal AI [7]. EFECT was a randomized,
double-blind, placebo-controlled, multicenter phase III study, in
which a total of 693 postmenopausal women with hormone
receptor-positive advanced breast cancer progressing or recurring
after non-steroidal AI were randomized to receive exemestane
(25 mg, orally once daily) or fulvestrant (500 mg intramuscularlyon day 0; 250 mg on days 14 and 28; and 250 mg every 28 days
thereafter).
Median TTP was 3.7 months in both groups (HR: 0.96; 95% CI;
0.82e1.13; p ¼ 0.653); whereas ORR was 7.4% and 6.7% in the ful-
vestrant and exemestane arms (OR: 1.12; 95% CI: 0.58e2.19;
p ¼ 0.736), respectively; and CBR was 32.2% and 31.5% (OR: 1.03;
95% CI: 0.72e1.49; p ¼ 0.853), respectively. The median duration of
response, as measured from the date of random assignment, was
13.5 months in the fulvestrant arm and 9.8 months in the
exemestane arm. The authors concluded that both drugs have
similar activity in a signiﬁcant proportion of postmenopausal
women with hormone receptor-positive advanced breast cancer
after progression on a non-steroidal AI [29].Fulvestrant plus anastrozole in comparison with anastrozole
Some questions still remain unanswered regarding the optimal
use of fulvestrant in the treatment of breast cancer, as the role of
the combination of fulvestrant with an AI. Fulvestrant may be more
effective in a low-estrogen environment, and this is supported by
preclinical data [30,31]. The combination of letrozole plus fulves-
trant was shown to be more effective in suppressing tumor growth
than either letrozole or anastrozole or fulvestrant alone. Subse-
quently, two randomized trials have demonstrated the efﬁcacy of
the combination of fulvestrant and anastrozole as ﬁrst-line treat-
ment for patients with metastatic breast cancer [32,33]. In the
open-label, prospective, randomized and phase III Fulvestrant and
Anastrozole Combination Therapy (FACT) trial, a total of 514 post-
menopausal women, or premenopausal women treated with
gonadotropin-releasing hormone agonist, with advanced hormone
receptor-positive breast cancer, were randomly assigned to receive
fulvestrant (500 mg on day 1, and 250 mg on days 15, 29 and
thereafter every 4 weeks) in combination with anastrozole (1 mg
per day) or anastrozole alone at the same dosage [32]. It was
observed that all efﬁcacy outcomes evaluated such as TTP, ORR,
CBR, duration of response and OS were similar between both
treatment arms. In a similarly designed randomized, phase III trial
performed by the Southwest Oncology Group (SWOG), 707 post-
menopausal women with hormone receptor-positive metastatic
breast cancer, without prior chemotherapy or immunotherapy for
metastatic disease, were randomized to fulvestrant plus anas-
trozole or anastrozole alone at the same doses as the FACT trial [33].
Overall, median progression-free survival (PFS) was 15.0months
and 13.5 months in the combination and the anastrozole arms (HR
for progression or death with the combination therapy: 0.80; 95%
CI: 0.68e0.94; p ¼ 0.007 by the log-rank test), respectively. Dif-
ferences were even higher (no prespeciﬁed analyses) in 414 pa-
tients (59.7%) who did not receive prior tamoxifen therapy (17.0
months vs. 12.6 months, respectively; HR for progression or death
with the combination therapy: 0.74; 95% CI: 0.59e0.92; p ¼ 0.006
by the log-rank test), whereas it did not achieve statistical signiﬁ-
cance among 280 women (40.3%) previously treated with tamox-
ifen (13.5 months vs. 14.1 months, respectively; HR: 0.89; 95% CI:
0.69e1.15; p ¼ 0.37 by the log-rank test). OS was also longer in
patients treated with the combination than in those who received
anastrozole alone (47.7 months vs. 41.3 months, respectively; HR
for death: 0.81; 95% CI: 0.65e1.00; p ¼ 0.05 by the log-rank test),
despite the fact that 41% of patients in the anastrozole arm crossed
over to fulvestrant after progression. Differences between trials
could explain the discrepancy in results. In the SWOG trial 40% of
patients had prior exposure to adjuvant tamoxifen, whereas this
percentage rose to 70% in the FACT trial. Moreover, in the SWOG
trial when patients were stratiﬁed according to prior tamoxifen
exposure, only patients without previous tamoxifen showed sta-
tistically signiﬁcant differences in terms of PFS.
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One of the approaches to optimizing the use of fulvestrant in
breast cancer is the investigation of higher doses.Previous rationale
A multicenter, randomized and partially blinded study
compared the effects of different doses of fulvestrant with tamox-
ifen or placebo on estrogen receptor and progesterone receptor
levels, Ki-67 proliferation-associated antigen labeling index (Ki-
67LI), and the apoptotic index in the primary breast tumors of
postmenopausal women [13]. A total of 201 women with primary
breast cancer were randomized to receive a single intramuscular
dose of fulvestrant (either of 50 mg, 125 mg or 250 mg), oral
tamoxifen (20 mg daily) or matching tamoxifen placebo for 14e21
days before tumor resection surgery with curative intent. Fulves-
trant produced dose-dependent reductions in estrogen receptor
and progesterone receptor H-scores as well as in the Ki-67LI. The
reduction of estrogen receptor expression was signiﬁcantly higher
with all doses of fulvestrant when compared with placebo (50 mg,
p ¼ 0.026; 125 mg, p ¼ 0.006; 250 mg, p ¼ 0.0001), and with ful-
vestrant 250 mg when compared with tamoxifen (p ¼ 0.024).
However, the reduction of progesterone receptor was only signiﬁ-
cant with fulvestrant 125 mg (p ¼ 0.003) and 250 mg (p ¼ 0.0002)
compared with placebo.
Additionally, all doses of fulvestrant signiﬁcantly reduced Ki-
67LI compared with placebo (50 mg, p ¼ 0.046; 125 mg,
p ¼ 0.001; 250 mg, p ¼ 0.0002), but there were no signiﬁcant dif-
ferences in this variable between any doses of fulvestrant and
tamoxifen. Finally, fulvestrant did not alter the apoptotic index
when compared with either placebo or tamoxifen (p ¼ 0.238).
These results showed that fulvestrant produced a marked dose-
dependent reduction in estrogen and progesterone receptor
expression, and Ki-67LI. However, it is important to consider that
these results may have been inﬂuenced by a less-than-optimal
exposure of both fulvestrant and tamoxifen during the study, as
the time to steady-state for tamoxifen is about 4 weeks and that for
fulvestrant is 3e6 months [3,34].Neoadjuvant setting
The Neoadjuvant Endocrine Therapy for Women with
Estrogen-Sensitive Tumors (NEWEST), open-label, randomized
phase II study compared fulvestrant at 500 mg with 250 mg as
neoadjuvant endocrine therapy in terms of biological activity
(expression of estrogen and progesterone receptors, and Ki-67LI),
ORR and tolerability in postmenopausal patients with locally
advanced breast cancer [35]. A total of 211 women were allocated
to receive 500 mg (plus 500 mg on day 14 of the ﬁrst month) vs.
250 mg per month of fulvestrant for 16 weeks before surgery. At
week 4, according to H score, the dose of 500 mg resulted in a
greater reduction of estrogen and progesterone receptor as well
as in Ki-67LI compared with the dose of 250 mg (p < 0.0001,
p ¼ 0.0018, p < 0.0001, respectively). Although the results of this
study may provide evidence of greater biological activity for the
500 mg dose of fulvestrant, differences may be also attributable
to the loading element of fulvestrant undertaken in the fulves-
trant 500 mg arm, as the steady-state in this treatment arm was
reached at 4 weeks.Efﬁcacy of fulvestrant 500 mg in the metastatic setting
After neoadjuvant data of the efﬁcacy of Fulvestrant 500 mg,
different studies were designed in the metastatic setting [13,35,36].FIRST trial
The Fulvestrant First-Line Study Comparing Endocrine Treat-
ment (FIRST) was a multicenter, open-label, randomized, phase II
trial that compared the efﬁcacy of fulvestrant 500 mg with anas-
trozole in the ﬁrst-line setting [37,38]. In total, 205 postmenopausal
patients with hormone receptor-positive locally advanced or met-
astatic breast cancer who were not amenable to therapy of curative
intent were randomly assigned to receive 500 mg of fulvestrant
monthly plus 500 mg on day 14 of the ﬁrst month or 1 mg/day of
anastrozole. The primary endpoint was CBR deﬁned as the pro-
portion of patients experiencing an objective response or stable
disease for at least 24 weeks.
Although there were no signiﬁcant differences between ful-
vestrant and anastrozole in terms of CBR and ORR (p ¼ 0.386 for
CBR and p ¼ 0.947 for ORR), the observed CBR conﬁrmed the high
clinical efﬁcacy of both agents. In contrast, median TTP was
signiﬁcantly longer with fulvestrant than with anastrozole (23.4
months vs. 13.1 months, respectively; HR: 0.66; 95% CI: 0.47e0.92;
p ¼ 0.01), corresponding to a 34% reduction in the risk of pro-
gression. KaplaneMeier curves for TTP indicate that fulvestrant
500 mg may be of beneﬁt for early progressive patients. This
treatment effect was consistent across all pre-deﬁned subgroups.
Also, reﬂecting the TTP advantage of fulvestrant over anastrozole,
duration of response, duration of clinical beneﬁt and time to
treatment failure (TTF) favored fulvestrant. Median TTF was 17.6
months with fulvestrant and 12.7 months with anastrozole (HR:
0.73; 95% CI: 0.54e1.00; p ¼ 0.05). This trial shows that another
endocrine agent may be more effective than an AI in this setting.
Taking into account that these results are from a randomized phase
II open-label trial, a phase III registration trial needs to be per-
formed to conﬁrm the role of fulvestrant 500 mg in this setting.
CONFIRM trial
Results of prior research led to the design of the Comparison
of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM)
study, a multicenter, double-blind, phase III trial that included
736 postmenopausal patients with locally advanced or recurrent
estrogen receptor-positive breast cancer who experienced pro-
gression after prior endocrine therapy with tamoxifen or AIs
[36,39]. Patients were randomized to receive 500 mg of fulves-
trant (500 mg on day 0, 14, 28, and every 28 days thereafter) or
250 mg of fulvestrant every 28 days. Results showed that the
500 mg regimen of fulvestrant was associated with a signiﬁcantly
longer PFS than the 250 mg regimen (6.5 months vs. 5.5 months,
respectively; HR: 0.80; 95% CI: 0.68e0.94; p ¼ 0.006); however,
similar results were obtained in terms of ORR (p ¼ 0.795) and
CBR (p ¼ 0.100). In a longer not pre-planned follow-up analyses
[39], median OS was signiﬁcantly longer with 500 mg of fulves-
trant than with 250 mg (26.4 months vs. 22.3 months; HR: 0.81;
95% CI: 0.69e0.96; p ¼ 0.016). The beneﬁt in terms of OS
demonstrated by fulvestrant in the CONFIRM trial is a key aspect
in this setting, because very few drugs have demonstrated im-
provements in OS in patients with metastatic breast cancer. From
the publication of the results of this trial, Fulvestrant at 500 mg
has become the preferred schedule for this drug.
Efﬁcacy of fulvestrant 250 mg and 500 mg in the metastatic setting
Martín et al. [40], designed the randomized, open label, phase III
LEA trial to address the hypothesis that anti-vascular endothelial
growth factor (anti-VEGF) treatment can prevent resistance to
hormone therapy in patients with endocrine responsive advanced
breast cancer. This trial assessed the combination of bevacizumab
with letrozole or fulvestrant (250 mg) as ﬁrst-line therapy in 380
patients with these characteristics. This study failed to demonstrate
E. Ciruelos et al. / The Breast 23 (2014) 201e208 205a statistically signiﬁcant increase in terms of PFS for the combina-
tion of endocrine therapy and bevacizumab in comparison with
endocrine therapy alone. In addition, the combination did not
demonstrate an impact on OS either.
Safety of fulvestrant 250 mg and 500 mg in advanced breast
cancer
In the European and American trials (Trial 0020 and Trial 0021)
that compared fulvestrant 250 mg with anastrozole, both treat-
ments were well tolerated, with a similar incidence of adverse
events [21,22,26]. The only signiﬁcant difference observed was the
incidence of joint disorders, including arthralgia, arthrosis and
arthritis, which occurred more frequently in patients receiving
anastrozole (p ¼ 0.0234) (Table 1). The most common adverse
events in both treatment groups, were nausea (26.0% vs. 25.3%),
asthenia (22.7% vs. 27.0%), pain (18.9% vs. 20.3%), vasodilation (17.7%
vs. 17.3%), and headache (15.4% vs. 16.8%) for the fulvestrant group
and the anastrozole group, respectively. Withdrawals due to drug-
related adverse events were 0.9% and 1.2% in the fulvestrant arm
and the anastrozole arm, respectively. The CONFIRM trial showed
that both doses of fulvestrant (250 mg and 500 mg) were well
tolerated with no substantial differences in the incidence and
severity of prespeciﬁed adverse events (Table 1). Also, the quality of
life between arms was similar with both dosages [36]. Serious
adverse events reported in more than 2 patients were bronchitis,
dyspnea, and vomiting in the 500 mg group, and there were no
cases reported in the 250 mg group.
Data from the FIRST trial showed that fulvestrant 500 mg was
well tolerated with an adverse events proﬁle comparable to that of
anastrozole and consistent with that previously reported in the
CONFIRM trial and NEWEST trials [35e37]. The incidence of serious
adverse events was 11.9% with fulvestrant 500 mg and 9.7% with
anastrozole. There were no signiﬁcant differences between treat-
ments in the incidence of any of the prespeciﬁed adverse events
(Table 1). The most common adverse events in the fulvestrant
500 mg arm were bone pain (13.9%), nausea (10.9%), arthralgia
(9.9%), constipation (9.9%), vomiting (8.9%) and dyspnea (8.9%). In
the anastrozole arm, the most common adverse events were hot
ﬂashes (13.6%), headache (12.6%), bone pain (9.7%), arthralgia
(8.7%) and myalgia (8.7%). The incidence of arthralgia was similar
between the two arms, but headache and asthenia were less
frequent in the fulvestrant arm [37].
Other mentioned trials showed no differences in terms of safety
data of fulvestrant in comparisonwith the control drugs, such as the
EFECTand the FACT trials [7,32]. Only the FACT trial showed a higher
incidence of hot ﬂashes in the combination arm compared with the
single treatment arm (p¼ 0.003) [32]. In general, fulvestrant is wellTable 1
Adverse events observed in patients treated with different endocrine therapies.
Adverse events 0020 and 0021 trials [27]
Fulvestrant
250 mg
N ¼ 428
n (%)
Anastrozole
1 mg
N ¼ 423
n (%)
Gastrointestinal disturbances 206 (49) 192 (45)
Hot ﬂashes 92 (22) 94 (22)
Injection site reactions NR NR
Ischemic cardiovascular disorders NR NR
Joint disorders 35 (8)a 54 (13)a
Thromboembolic events 15 (4) 19 (5)
Urinary tract infection 37 (9) 25 (6)
Vaginitis 11 (3) 8 (2)
Weight gain 6 (1) 9 (2)
a Only this adverse event is signiﬁcantly different in both treatment arms (p ¼ 0.0234tolerated, with no signiﬁcant toxicities and very low frequency of
treatment dropout. This is essential in the treatment of advanced
breast cancer, where treatment tolerance and quality of life should
be important factors in treatment decisions. In addition, there were
no signiﬁcant differences between the toxicity proﬁles of fulvestrant
and other hormonal therapies such as anastrozole, tamoxifen and
exemestane, or between both doses of fulvestrant in the treatment
of hormone-sensitive advanced breast cancer.
Ongoing research with fulvestrant in breast cancer
As described previously, patients with estrogen receptor-
positive breast cancer beneﬁt from AI as ﬁrst-line therapy, but
many of them develop resistance to these drugs due to the upre-
gulation of signaling pathways such as phosphoinositide-3-kinase
(PI3K)/Akt/mammalian target of rapamycin (mTOR) and human
epidermal growth factor receptor type 2 (HER2)/mitogen-activated
protein kinase (MAPK) [41e43].
Fulvestrant in combination with mTOR-PI3KCA inhibitors
Preclinical studies had demonstrated that the sensitivity to
hormonal therapy may be restored by treatment with mTOR in-
hibitors such as everolimus [44]. Subsequently, a randomized phase
II trial showed that everolimus signiﬁcantly increased letrozole
efﬁcacy in the neoadjuvant setting in patients with estrogen
receptor-positive breast cancer [45]. Also, a randomized phase III
trial showed that everolimus in combination with an AI such as
exemestane improved PFS over exemestane alone (6.9 months vs.
2.8 months; p < 0.001) in women with hormone receptor-positive
advanced breast cancer previously treated with non-steroidal AI
[46]. The combination of everolimus with tamoxifen also increased
CBR, TTP and OS compared with tamoxifen alone in post-
menopausal women with hormone receptor-positive, HER2-nega-
tive and AI resistant metastatic breast cancer [47].
According to these results and taking into account that fulves-
trant is one standard option for second-line hormonal treatment,
several ongoing trials are testing the combination of fulvestrant
with PI3K inhibitors, such as BYL719, GDC-0941, GDC-0980 and
BKM120. BYL719 is an oral PI3K inhibitor that strongly and selec-
tively inhibits the PI3Ka isoform of PI3K and shows statistically
signiﬁcant dose-dependent anti-tumor efﬁcacy in PIK3CA mutant
xenograft models in rodents [48]. In an ongoing phase I trial,
BYL719 as single agent or in combination with fulvestrant is being
administered to patients with estrogen receptor-positive PIK3CA-
mutated advanced breast cancer progressed despite standard
therapy or for whom no standard therapy exists (ClinicalTrials.gov
identiﬁer NCT01219699).CONFIRM trial [36] FIRST trial [37]
Fulvestrant
250 mg
N ¼ 374
n (%)
Fulvestrant
500 mg
N ¼ 361
n (%)
Fulvestrant
500 mg
N ¼ 101
n (%)
Anastrozole
1 mg
N ¼ 103
n (%)
76 (20) 73 (20) 28 (28) 23 (22)
23 (6) 30 (8) 13 (13) 14 (14)
50 (13) 49 (14) NR NR
7 (2) 5 (1) 0 (0) 1 (1)
70 (19) 68 (19) 14 (14) 10 (10)
0 (0) 3 (1) 0 (0) 0 (0)
8 (2) 8 (2) 4 (4) 1 (1)
1 (0.3) 3 (1) 0 (0) 0 (0)
1 (0.3) 1 (0.3) 1 (0) 0 (0)
). NR: not reported.
Fig. 2. Treatment algorithm for postmenopausal patients with hormone receptor-positive and HER2-negative breast cancer.* AI: aromatase inhibitor; CT: chemotherapy; DFI:
disease-free interval; EE: exemestane plus everolimus; FUL: fulvestrant; HER2: human epidermal growth factor receptor type 2; HR: hormone receptor; RT: radiotherapy; TAM:
tamoxifen. Short DFI: relapse occurs during adjuvant treatment administration or within the ﬁrst 12 months after ﬁnishing it. Long DFI: relapse occurs after 12 months from the end
of adjuvant hormonal treatment administration. *All treatment decisions should take into account the toxicity proﬁle of different drugs and patient preferences.
E. Ciruelos et al. / The Breast 23 (2014) 201e208206The discovery of potent, selective class I PI3K and mTOR kinase
inhibitors for the treatment of cancer has led to their clinical
development for breast disease. Currently, a double-blind, placebo-
controlled, randomized phase II trial is comparing two orally
available PI3K and mTOR inhibitors, GDC-0941 and GDC-0980, in
combination with fulvestrant, with fulvestrant alone in patients
with advanced breast cancer who are resistant to AI therapy
(ClinicalTrials.gov identiﬁer NCT01437566). Preliminary results are
expected at the end of 2015.
BKM120 is another potent andhighly speciﬁc oral pan-class I PI3K
inhibitor. Unlike other inhibitors, it does not inhibit the relatedmTOR
and Vps34 kinases. Currently, two randomized phase III trials are
evaluating the role of this drug in the treatment of patients with
hormone receptor-positive, HER2-negative locally advanced or
metastatic breast cancer. The BELLE-2 study is testing the combina-
tionof fulvestrantwithorwithoutBKM120 inpatients refractory toAI
(ClinicalTrials.gov identiﬁer NCT01610284). The BELLE-3 study is
evaluating the combinationof fulvestrantwithorwithout BKM120 in
patients who have progressed on or after a mTOR inhibitor-based
treatment (ClinicalTrials.gov identiﬁer NCT01633060).
Fulvestrant in combination with EGFR inhibitors
Geﬁtinib is a selective inhibitor of the epidermal growth factor
receptor (EGFR), this receptor is overexpressed in certain types of
human carcinomas, such as lung and breast cancer. A phase II trial
evaluating the efﬁcacy of the combination of geﬁtinib 250 mg with
fulvestrant 250 mg in advanced or metastatic breast cancer with
estrogen receptor-positive and/or progesterone receptor-positive
disease has been completed recently (ClinicalTrials.gov identiﬁer
NCT00234403).
Fulvestrant as ﬁrst-line treatment
Lastly, the FALCON study, a multicenter, double-blind, random-
ized, phase III trial is currently ongoing to compare the efﬁcacy in
terms of PFS and tolerability of fulvestrant 500mgwith anastrozole
1 mg as endocrine treatment for postmenopausal women with
hormone receptor-positive locally advanced or metastatic breastcancer who have not previously been treated with any hormonal
therapy (Clinicaltrials.com identiﬁer NCT01602380). This trial could
change future recommendations of hormonal therapy in the ﬁrst-
line setting.
Fulvestrant for premenopausal patients
Fulvestrant has been studied little in premenopausal women
despite of its attractive mechanism of action. Nonetheless, a ran-
domized phase II trial is currently studying the combination of
fulvestrant with goserelin an injectable gonadotropin-releasing
hormone superagonist used for ovarian suppression in premeno-
pausal women. In this trial, the activity of fulvestrant plus goserelin
is compared with anastrozole plus goselerin and goselerin alone in
premenopausal women with recurrent or metastatic estrogen
receptor-positive breast cancer (ClinicalTrials.gov identiﬁer
NCT01266213).
The current therapeutic role of fulvestrant in breast cancer
AIs are the preferred treatment approach for most post-
menopausal women with hormone receptor-positive advanced
breast cancer, but many of these patients progress or become
resistant to these drugs. Fulvestrant has been demonstrated to be
active in patients with breast cancer previously treated with
tamoxifen or non-steroidal AI. This beneﬁt was seen in two phase III
trials with fulvestrant at 250 mg (32.2e39.6%) and 500 mg (45.6%)
in patients resistant to a previous AI [7,36]. Fulvestrant was also
shown to be effective in breast cancer patients previously untreated
with hormonal therapy (FIRST trial) with a higher clinical beneﬁt
than anastrozole [37,38]. The NEWEST trial demonstrated the efﬁ-
cacy of fulvestrant in the neoadjuvant setting at a dose of 500 mg
[35]. Taking into account its different mechanism of action, ful-
vestrant may be administered with a LHRH agonist to premeno-
pausal women with breast cancer. Several studies have evaluated
fulvestrant in premenopausal women with breast cancer and
compared results with placebo or tamoxifen [49], with an adequate
safety and efﬁcacy proﬁle (TTP 5 months and CBR 45.5%). Fulves-
trant has also shown a good and predictable safety proﬁle in several
E. Ciruelos et al. / The Breast 23 (2014) 201e208 207randomized trials [7,27,28,32,33], even at high doses (FIRST and
CONFIRM trials) [37].
Another potential advantage of fulvestrant is that itmay improve
treatment compliance due its monthly parenteral administration
compared with daily oral intakes of other endocrine therapies.
Adherence of oral long-term treatments is a major problem that
should be considered [50]. It is estimated that around 20% of breast
cancer patients receiving oral endocrine therapy do not take their
medication regularly, primarily in the adjuvant setting where
beneﬁt of treatment is not clearly perceived by patients [51].
Parenteral administration of fulvestrant provides greater control
over endocrine treatment compliance, reducing oral absorption and
pharmacokinetic interactions with food or other drugs, which are
important aspects to be considered in patients with breast cancer
who usually are receiving multiple medications. Lastly, fulvestrant
may be effectively combined also with targeted drugs. Due to
greater understanding of the molecular pathways involved in the
development of cancer, several trials are evaluating the role of new
biological drugswhich block signaling pathways. Newdrugs such as
the mTOR inhibitor everolimus, and the PI3K inhibitors such as
BYL719, GDC-0941, GDC-0980, and BKM120, are being assessed in
combination with fulvestrant for the treatment of breast cancer.
Fig. 2 describes a treatment algorithm for postmenopausal patients
with hormone receptor-positive and HER2-negative breast cancer.
Conclusions
Fulvestrant is a SERD that does not have the agonist activity seen
with tamoxifen, so it can be administered in postmenopausal
women with hormone receptor-positive advanced breast cancer
who have disease progression on tamoxifen or AI. Research is also
focused in premenopausal women, with optimal results so far.
Fulvestrant has also been shown to be active in patients previously
untreated with endocrine therapies, either in the neoadjuvant or in
themetastatic setting, alone or in combinationwith other therapies
such as AI or targeted drugs. Higher doses, i.e. 500 mg of fulves-
trant, have proven to be more effective than the dose of 250 mg,
without any signiﬁcant difference in the toxicity proﬁle. Taking all
these factors together, fulvestrant is an alternative for patients with
hormone-responsive advanced breast cancer who have progressed
on other endocrine therapies and who need a well-tolerated
alternative that improves treatment compliance.
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